Annex I
Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
**Scientific conclusions**

Based on the analysis of cases from Eudravigilance and literature, despite possible confounding factors such as multiple medication administration or underlying medical history, 16 cases of interest were identified in EudraVigilance, most of them based on literature articles. Additionally, there were at least 4 cases of Kounis syndrome with confirmed hypersensitivity to rocuronium, i.e. positive skin prick test. Moreover, two literature cases also reported a positive rechallenged and in one of them the prick testing performed had a positive result for rocuronium bromide and negative to the other drugs administered.

Considering the data presented above, the temporal association between rocuronium administration and Kounis syndrome could not be excluded. Taking into account the potentially life-threatening course of Kounis syndrome, the PRAC proposes to update the product information of rocuronium containing medicinal products to add Kounis syndrome with the frequency ‘not known’.

The CMDh agrees with the scientific conclusions made by the PRAC.

**Grounds for the variation to the terms of the Marketing Authorisation(s)**

On the basis of the scientific conclusions for rocuronium the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing rocuronium is unchanged subject to the proposed changes to the product information.

The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing rocuronium are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.
Annex II
Amendments to the product information of the nationally authorised medicinal product(s)
The following changes to the product information of medicinal products containing the active substance rocuronium are recommended (new text underlined and in bold, deleted text strike through):

**Summary of Product Characteristics**

- Section 4.8

The following adverse reaction(s) should be added under the SOC Cardiac disorders with a frequency “not known”:

**Kounis syndrome**

**Package Leaflet**

Section 4: Possible side effects

*Not known (frequency cannot be estimated from the available data):*

*Severe allergic coronary blood vessels spasm (Kounis syndrome) resulting in chest pain (angina) or heart attack (myocardial infarction)*
Annex III
Timetable for the implementation of this position
<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adoption of CMDh position:</td>
<td>November 2019 CMDh meeting</td>
</tr>
<tr>
<td>Transmission to National Competent Authorities of the translations of the annexes to the position:</td>
<td>26 January 2020</td>
</tr>
<tr>
<td>Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):</td>
<td>27 March 2020</td>
</tr>
</tbody>
</table>